Mobocertinib not checked
Millennium Pharmaceuticals, Inc. · TAK-788 · AP32788
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- Tested for
- Non-Small Cell Lung Cancer
- Main trialPhase 1
- “This study is in 2 parts. Different participants will take part in the 1st and 2nd parts of the study. The main aim of the 1st part of the study is to check how much Mobocertinib adults with non-small cell lung cancer (NSCLC) can receive without getting side effects from it. The main aim of the 2nd part of the study is to learn if the condition of adults with non-small cell lung cancer improves after treatment with Mobocertinib. Another aim is to continue checking for side effects from Mobocertinib. In the 1st part of the study, at the first visit, the study doctor will check who can take…”In the company’s words, NCT03807778 on ClinicalTrials.gov
- Other names
- TAK-788 · AP32788
Other drugs for Non-Small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 8 Nov 2021 | A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer | |
| Phase 3Completed | 22 Sep 2026 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | |
| Phase 1/2Completed | 29 Sep 2026 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | |
| Phase 1Completed | 11 Mar 2019 | A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants | |
| Phase 1Completed | 10 Aug 2020 | A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants | |
| Phase 1Completed | 17 Dec 2020 | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | |
| Phase 1Completed | 5 Feb 2022 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function | |
| Phase 1Completed | 20 Apr 2022 | A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026